Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iscalimab by Novartis for Lupus Nephritis: Likelihood of Approval
Iscalimab is under clinical development by Novartis and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II...
Iscalimab by Novartis for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval
Iscalimab is under clinical development by Novartis and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to...
CALY-002 by Novartis for Celiac Disease: Likelihood of Approval
CALY-002 is under clinical development by Novartis and currently in Phase I for Celiac Disease. According to GlobalData, Phase I...
Ribociclib succinate by Novartis for Neuroendocrine Tumors: Likelihood of Approval
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...
Ruxolitinib phosphate by Novartis for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Ruxolitinib phosphate is under clinical development by Novartis and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Trametinib dimethyl sulfoxide by Novartis for Juvenile Myelomonocytic Leukemia (JMML): Likelihood of Approval
Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Juvenile Myelomonocytic Leukemia (JMML). According...
Siremadlin succinate by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Siremadlin succinate by Novartis for Metastatic Colorectal Cancer: Likelihood of Approval
Siremadlin succinate is under clinical development by Novartis and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
Trametinib dimethyl sulfoxide by Novartis for Relapsed Multiple Myeloma: Likelihood of Approval
Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Relapsed Multiple Myeloma. According to...
Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?
Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Novartis's Atrasentan hydrochloride?
Atrasentan hydrochloride is a small molecule commercialized by Novartis, with a leading Pre-Registration program in IgA Nephropathy (Berger's Disease). According...
Tesidolumab by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Tesidolumab is under clinical development by Novartis and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase...
Crizanlizumab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...
Crizanlizumab by Novartis for Myelofibrosis: Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
LKA-651 by Novartis for Diabetic Macular Edema: Likelihood of Approval
LKA-651 is under clinical development by Novartis and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase...
Sabatolimab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...
Risk adjusted net present value: What is the current valuation of Novartis's Pelacarsen Sodium?
Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to...
Risk adjusted net present value: What is the current valuation of Novartis's Peptide to Antagonize GRPR for Oncology?
Peptide to Antagonize GRPR for Oncology is a peptide commercialized by Novartis, with a leading Phase II program in Metastatic...
Risk adjusted net present value: What is the current valuation of Novartis's LNA-043?
LNA-043 is a biologic commercialized by Novartis, with a leading Phase II program in Osteoarthritis. According to Globaldata, it is...
Risk adjusted net present value: What is the current valuation of Novartis's Iscalimab?
Iscalimab is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Lupus Nephritis. According to Globaldata,...